Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts
Open Access
- 30 March 2005
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 116 (2) , 253-262
- https://doi.org/10.1002/ijc.21008
Abstract
The invasion of oral squamous cell carcinoma (SCC) cells into the mandibular bone is a common clinical problem. It has been reported that BHY cells, a human oral SCC cell line, are capable of invading mandibular bone of nude mice. These results led us to examine possible mechanisms of osteoclastogenesis induced by BHY cells using in vitro culture systems. When BHY cells were cocultured with mouse bone marrow cells (BMCs), only few osteoclasts were formed, even though BHY cells express the receptor activator of NF-κB ligand (RANKL). However, adding BHY cells to a coculture of mouse primary osteoblasts (POBs) and BMCs markedly induced osteoclastogenesis in the absence of osteotropic factors. Furthermore, another oral SCC cell line, HSC-2, which does not express RANKL, also induced osteoclastogenesis in our cocultures. These effects were significantly, but not completely, inhibited by adding osteoprotegerin (OPG). In addition, we also found that TNFα released from these cells partially contributes to osteoclastogenesis via a RANKL-independent mechanism. Adding BHY or HSC-2 cells suppressed mouse OPG mRNA expression and protein production by POBs in cocultures of POBs and human oral SCC cells. This finding is consistent with the result that BHY cells and HSC-2 cells did not enhance osteoclastogenesis in cocultures of BMCs and POBs from OPG-deficient mice. Immunohistochemical analysis showed a reduction of OPG expression in osteolytic lesions as compared to normal lesions from oral SCC patients. Therefore, oral SCC-induced suppression of OPG expression in POBs appears critical for osteoclastogenesis, rather than expression of RANKL in SCC cells.Keywords
This publication has 41 references indexed in Scilit:
- Breast Cancer Metastasis to BoneClinical Orthopaedics and Related Research, 2003
- RANKL and RANK as novel therapeutic targets for arthritisCurrent Opinion in Rheumatology, 2003
- Osteoclast differentiation and activationNature, 2003
- Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone diseaseBlood, 2002
- Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsBlood, 2002
- Monitoring Metastatic Behavior of Human Tumor Cells in Mice with Species-Specific Polymerase Chain Reaction: Elevated Expression of Angiogenesis and Bone Resorption Stimulators by Breast Cancer in Bone MetastasesJournal of Bone and Mineral Research, 2001
- Cancer Cells Responsible for Humoral Hypercalcemia Express mRNA Encoding a Secreted Form of ODF/TRANCE That Induces Osteoclast FormationBiochemical and Biophysical Research Communications, 2000
- Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritisArthritis & Rheumatism, 2000
- Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory FactorPublished by Elsevier ,1998
- Regulation of Osteoclast FunctionJournal of Bone and Mineral Research, 1997